iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 636 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept MOST POPULAR Trial Results Support SBRT as a Standard Option for Some Prostate... November 21, 2024 ¿El azúcar provoca cáncer? September 20, 2022 Welcome to Caring Connections November 18, 2020 Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Tislelizumab Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... High Frequency of Germline ATM Variants in CLL 2022 ASCO Annual Meeting Research Round Up: New Research in Head...
